IncobotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation

Conditions

Ill-Defined Sites

What is the purpose of this trial?

The scientific aim this study is to investigate the efficacy of incobotulinumtoxinA (Xeomin) in the treatment of post-surgical/post radiation cancer pain. Botulinum type A toxins are shown to have a potent analgesic effect. Our hypothesis is that injection of incobotulinumtoxinA into the area of local pain at or around the area of post-surgical/post radiation scar relieves the focal cancer pain.


Participation Guidelines

Age:
18 Years - 80 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Merz Pharmaceuticals
Dates:
09/07/2012
Last Updated:
Study HIC#:
1205010328